CLINICAL_TRIALS
trial_result
· 2023-12-13
Clinical Trial Update: Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease [Phase 3]
Summary
A Phase 3 trial evaluating efficacy and tolerability of lubiprostone in patients with nonalcoholic fatty liver disease (NAFLD) has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Helwan University | Conditions: NAFLD | Phase 3 | Status: COMPLETED